Leap Therapeutics (LPTX) News Today $0.36 -0.01 (-1.52%) Closing price 04:00 PM EasternExtended Trading$0.36 0.00 (-0.39%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerApril 15 at 7:00 AM | prnewswire.comLeap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study TranscriptMarch 31, 2025 | seekingalpha.comH.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)March 27, 2025 | markets.businessinsider.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | finanznachrichten.deLeap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | prnewswire.comLeap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | prnewswire.comWhat is HC Wainwright's Estimate for LPTX FY2029 Earnings?Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Leap Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per shaJanuary 30, 2025 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Downgraded to Hold Rating by Baird R WBaird R W cut shares of Leap Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday.January 30, 2025 | marketbeat.comLeap Therapeutics downgraded to Neutral from Buy at H.C. WainwrightJanuary 29, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)January 29, 2025 | msn.comLeap Therapeutics stock rating cut by H.C. Wainwright to NeutralJanuary 29, 2025 | msn.comLeap Therapeutics (NASDAQ:LPTX) Downgraded by HC Wainwright to NeutralHC Wainwright downgraded Leap Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday.January 29, 2025 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Stock Rating Lowered by Robert W. BairdRobert W. Baird lowered Leap Therapeutics from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $9.00 to $1.25 in a report on Wednesday.January 29, 2025 | marketbeat.comLeap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug ResultsJanuary 28, 2025 | marketwatch.comLeap Therapeutics stock hits 52-week low at $0.8January 28, 2025 | msn.comLeap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancerJanuary 28, 2025 | msn.comLeap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyJanuary 28, 2025 | prnewswire.comPositive Buy Rating for Leap Therapeutics Driven by Promising Clinical Results and Robust Pipeline AdvancementsJanuary 17, 2025 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $5.50 price target on shares of Leap Therapeutics in a research note on Thursday.January 16, 2025 | marketbeat.comLeap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon CancerJanuary 6, 2025 | seekingalpha.comLeap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Up 50.7% in DecemberLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,140,000 shares, an increase of 50.7% from the November 30th total of 1,420,000 shares. Based on an average trading volume of 352,300 shares, the days-to-cover ratio is currently 6.1 days. Approximately 7.5% of the shares of the company are sold short.December 28, 2024 | marketbeat.comLeap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | prnewswire.comBuy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial OutlookNovember 15, 2024 | markets.businessinsider.comLeap Therapeutics Reports Q3 2024 Progress and FinancialsNovember 15, 2024 | markets.businessinsider.comSimplify Asset Management Inc. Grows Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)Simplify Asset Management Inc. raised its stake in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 67.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,056,895 shares of the company's stock after buying anNovember 15, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.50 price target on shares of Leap Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comLeap Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | prnewswire.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Significant Drop in Short InterestLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 723,500 shares, a decline of 19.5% from the September 30th total of 899,100 shares. Based on an average daily trading volume, of 149,100 shares, the short-interest ratio is presently 4.9 days. Approximately 2.4% of the shares of the stock are short sold.October 27, 2024 | marketbeat.comLeap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsSeptember 30, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Stock Crosses Below Fifty Day Moving Average of $2.58Leap Therapeutics (NASDAQ:LPTX) Shares Cross Below 50-Day Moving Average of $2.58September 28, 2024 | marketbeat.comSimplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)Simplify Asset Management Inc. increased its position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 67.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 631,269 shares of the compaSeptember 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest UpdateLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 1,230,000 shares, a growth of 17.1% from the July 31st total of 1,050,000 shares. Approximately 4.1% of the company's shares are sold short. Based on an average trading volume of 134,000 shares, the short-interest ratio is presently 9.2 days.August 31, 2024 | marketbeat.comLeap Therapeutics Inc (5MC.MU)August 23, 2024 | sg.finance.yahoo.com3 Trending Biotech Penny StocksAugust 22, 2024 | 247wallst.comVanguard Group Inc. Acquires 457,904 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)Vanguard Group Inc. boosted its holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 111.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 867,708 shares of the company's stock after acquirAugust 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short InterestLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 1,050,000 shares, a decline of 7.1% from the July 15th total of 1,130,000 shares. Approximately 3.5% of the company's stock are short sold. Based on an average daily trading volume, of 145,200 shares, the short-interest ratio is presently 7.2 days.August 19, 2024 | marketbeat.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deQ3 2024 EPS Estimates for Leap Therapeutics, Inc. (NASDAQ:LPTX) Decreased by AnalystLeap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Leap Therapeutics in a research note issued to investors on Tuesday, August 13th. HC Wainwright analyst S. Ramakanth now forecasts that the compAugust 15, 2024 | marketbeat.comMaintained Buy Rating for Leap Therapeutics Amid Promising Clinical and Financial OutlookAugust 14, 2024 | markets.businessinsider.comLeap Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Trading Down 4.3%Leap Therapeutics (NASDAQ:LPTX) Shares Down 4.3%June 7, 2024 | marketbeat.comBuy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic ExpansionMay 14, 2024 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Given New $5.50 Price Target at HC WainwrightHC Wainwright decreased their price target on shares of Leap Therapeutics from $7.00 to $5.50 and set a "buy" rating for the company in a research note on Tuesday.May 14, 2024 | marketbeat.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024May 13, 2024 | investorplace.comLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13, 2024 | finanznachrichten.deLeap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Trading 0.6% Higher Leap Therapeutics (NASDAQ:LPTX) Trading Up 0.6%May 4, 2024 | marketbeat.comLeap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%April 11, 2024 | markets.businessinsider.com Remove Ads Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address LPTX Media Mentions By Week LPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPTX News Sentiment▼0.290.80▲Average Medical News Sentiment LPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPTX Articles This Week▼21▲LPTX Articles Average Week Remove Ads Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kronos Bio News Gain Therapeutics News Oncolytics Biotech News Verrica Pharmaceuticals News VolitionRx News PMV Pharmaceuticals News ImmuCell News Sutro Biopharma News PDS Biotechnology News Cue Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPTX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LPTX Stock Free LPTX Stock Alerts